ADMA Biologics, Inc. (ADMA)
$
8.29
-1.34 (-16.16%)
Key metrics
Financial statements
Free cash flow per share
0.1169
Market cap
2 Billion
Price to sales ratio
3.8699
Debt to equity
0.1674
Current ratio
6.7084
Income quality
0.3430
Average inventory
201.6 Million
ROE
0.3498
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics to address immune deficiencies and infectious diseases both in the United States and internationally. The company recorded a notable revenue of $510,173,000.00 showcasing its steady growth. Among its key offerings are BIVIGAM, an intravenous immune globulin (IVIG) product for treating primary humoral immunodeficiency (PI), ASCENIV, another IVIG product designed for the same condition, and Nabi-HB, indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen along with other potential exposures to Hepatitis B. Additionally, ADMA Biologics is developing a pipeline of plasma-derived therapeutics, including innovative products aimed at the treatment and prevention of S. pneumonia infections for immunoglobulin. The cost of revenue for the company is $217,408,000.00 showcasing its production and operational expenses, while the total costs and expenses for the company are $318,730,000.00 reflecting its overall spending. The company's stock is identified with the symbol 'ADMA' in the market, and the weighted average number of diluted shares outstanding is 244,904,640.00 indicating potential dilution effects. Moreover, the stock is affordable at $15.91 making it suitable for budget-conscious investors seeking opportunities. With a high average trading volume of 2,863,149.00 the stock demonstrates strong liquidity, which is an advantageous factor for traders. With a mid-range market capitalization of $1,974,338,110.00 the company is a steady performer in the biopharmaceutical realm. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth within the Healthcare sector. This dual focus on patient needs and robust market engagement aligns ADMA Biologics as an important entity shaping the future of plasma-derived therapeutics.
Is ADMA Biologics, Inc. (ADMA) a good investment?
Investing in ADMA Biologics, Inc. (ADMA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is ADMA Biologics, Inc. (ADMA)'s stock forecast?
Analysts predict ADMA Biologics, Inc. stock to fluctuate between $7.21 (low) and $25.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ADMA Biologics, Inc.'s market capitalization?
As of 2026-03-27, ADMA Biologics, Inc.'s market cap is $1,974,338,110, based on 238,159,000 outstanding shares.
How does ADMA Biologics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., ADMA Biologics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy ADMA Biologics, Inc. (ADMA) stock?
To buy ADMA Biologics, Inc. (ADMA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ADMA. Place an order (Market, Limit, etc.).
What is the best time to invest in ADMA Biologics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did ADMA Biologics, Inc. perform in the last earnings report?
Revenue: $510,173,000 | EPS: $0.62 | Growth: -27.06%.
Where can I find ADMA Biologics, Inc.'s investor relations reports?
Visit https://www.admabiologics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ADMA Biologics, Inc.?
You can explore historical data from here
What is the all-time high and low for ADMA Biologics, Inc. stock?
All-time high: $25.67 (2025-04-28) | All-time low: $1.01 (2021-10-21).
What are the key trends affecting ADMA Biologics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclos.
zacks.com
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
globenewswire.com
Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines
globenewswire.com
ADMA Biologics Hit with Securities Fraud Investigation After Stock Slides 29% Amid Channel Stuffing Claims – Investors with Losses Alerted to Contact BFA
businesswire.com
NEW YORK--(BUSINESS WIRE)---- $ADMA #ADMA--BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ADMA BIOLOGICS, INC. (ADMA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On.
globenewswire.com
ATLANTA, March 26, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) complied with federal securities laws. On March 24, 2026, Culper Research published a report alleging that “ADMA's reported growth is a fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor. We estimate that, absent channel stuffing, ADMA revenues declined 3% in 2025 vs. +20% reported.” Following this report, the price of the Company's stock dropped.
zacks.com
Adma Biologics (ADMA) closed the most recent trading day at $9.63, moving 15% from the previous trading session.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ADMA BIOLOGICS, INC. (ADMA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On March 24, 2026, Culper Research published a report alleging “Ch.
benzinga.com
• ADMA Biologics stock is testing key support levels. What's pressuring ADMA?
See all news
